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ABSTRACT: Noroviruses are the major causeof human epidemic nonbacterial gastroenteritis. Viral replication
requires a 3C cysteine protease that cleaves a 200 kDa viral polyprotein into its constituent functional
proteins. Here we describe the X-ray structure of the Southampton norovirus 3C protease (SV3CP) bound to
an active site-directed peptide inhibitor (MAPI) which has been refined at 1.7 A ˚ resolution. The inhibitor,
acetyl-Glu-Phe-Gln-Leu-Gln-X, which is based on the most rapidly cleaved recognition sequence in the
200kDapolyproteinsubstrate,reactscovalentlythroughitspropenylethylestergroup(X)withtheactivesite
nucleophile, Cys 139. The structure permits, for the first time, the identification of substrate recognition and
binding groups in a noroviral 3C protease and thus provides important new information for the development
of antiviral prophylactics.
Noroviruses are the most common cause of acute viral gastro-
enteritis in humans with epidemics being particularly common in
confined communities such as hospitals, schools, hotels, and
ocean liners and in the armed forces (1). The virus is transmitted
by the fecal-oral route through contaminated food and water,
bydirectcontact,andpossiblybytransmissionthroughair-borne
viral particles (2). Currently, there is neither vaccine nor antiviral
therapy available for the control of the disease, largely because
progress in studying human noroviruses has been greatly impeded
by the lack of a permissive cell culture system (3).
Comparisonsofgenomesequenceandorganizationhaveplaced
these viruses in the family Caliciviridae: a viral family consisting
of five currently recognized genera, one of which is the noro-
viruses (4, 5). Phylogenetic analyses have shown that animal and
human noroviruses can be classified into five separate gen-
ogroups, with the noroviruses infecting humans most commonly
occurring in genogroups 1 and 2. The prototype virus, Norwalk
virus,andtheSouthamptonvirus,usedinthisstudy,bothbelong
to genogroup 1. The Southampton norovirus genome consists of
amoleculeofsingle-strandedpositivesenseRNAof7708nucleotides
withapolyadenylated30 terminus(6,7).Thegenomeisorganized
intothreeopenreadingframes;ORF
11ispositionedatthe50 end
and encodes a large 200 kDa nonstructural polyprotein, ORF 2
encodes the major capsid protein VP1, and ORF 3 codes for a
small basic protein VP2 that is likely to assist in the assembly of
newly synthesized viruses (8).
In vitro translation and mutagenesis studies indicated that the
200 kDa ORF 1 polyprotein of Southampton virus is cleaved by
the action of a 3C protease to initially generate three separate
functional protein products (9). Full processing of the precursor
polyprotein generates six mature products (10): an N-terminal
protein (p48), an NTPase (p41), a 3A-like protein (p21), a Vpg
protein (p16), the 3C protease (p19), and an RNA polymerase
(p57),asshowninFigure1.Theproteasealsoinhibitstranslation
of host proteins by cleavage of the poly(A) binding protein,
thereby allowing preferential viral protein expression (11).
The scissile bonds cleaved by the Southampton virus protease
within its 200 kDa polyprotein substrate are within the dipeptide
recognition sequences Glu-Gly, Gln-Gly, or Gln-Ala, where the
“-” indicates the cleavage site (10). The protease has a preference
forcleavageatLQ-GPandLQ-GK,butitcanalsocleaveatME-
GK, FE-AP, and LE-GG. It appears that the enzyme preferen-
tiallyaccommodatesaglutamineresidueattheactivesiteS1posi-
tionbutwillalsoacceptaglutamateresidue.Sincetheproteolytic
processing of the 200 kDa precursor polyprotein is essential to
yield functional viral proteins, the viral protease presents itself as
a particularly viable target for antiviral strategies.
Enzymes in this family are cysteine proteases that display a
trypsin- or chymotrypsin-like serine protease fold, a property
which distinguishes this family from other viral proteases (12).
It has been shown for the human rhinovirus enzyme that the
preferred amino acids at the P3, P2, and P1 positions are
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Leu, Phe, and Gln, respectively (13). Modified peptide inhibitors
that include the preferred amino acid recognition sequence but
possessaC-terminalchemicalmoietycapableofreactingwiththe
active site cysteine residue have been developed, and in vitro
studies show that these completely inhibit the 3C protease acti-
vity (14, 15). One class of inhibitor includes a Michael-acceptor
group at its C-terminus (Figure 2), which undergoes nucleophilic
attack by the active site thiol, resulting in the inhibitor becoming
covalently and irreversibly bound to the catalytic cysteine (14).
Development of these peptide Michael-acceptor inhibitors has led
to compounds that not only inhibit human rhinovirus 3C protease
activity in vitro but also display antiviral properties in vivo (16).
From a comparison between norovirus protease amino acid
sequences and those of polio virus (PV), human rhinovirus
(HRV), hepatitis A virus (HAV), Chiba virus (CV), and foot
and mouth disease virus (FMDV), it is apparent that the norovirus
protease belongs to the same small family of (chymo)trypsin-like
cysteine proteases, as distinct from the more distant papain-like
cysteine proteases. This has been confirmed by the determination
of two X-ray crystal structures of the protease from group 1 noro-
virus (17, 18). Cysteine proteases typically possess an active site
dyad comprising cysteine and histidine. Interestingly, the three-
dimensional structures of the PV, HRV, HAV, FMDV, and CV
3C proteases indicate that a third amino acid, either aspartate or
glutamate, is present at the active site, as in all serine proteases.
However, site-directed mutagenesis of CV 3C protease has
suggested that the third acidic amino acid may not be essential
for activity (19).
This paper describes, for the first time, the X-ray structure of
the Southampton norovirus protease bound to a polypeptide
irreversible inhibitor (MAPI), acetyl-Glu-Phe-Gln-Leu-Gln-X,
in which the natural polyprotein substrate recognition sequence
is linked to a propenyl ethyl ester moiety (X). The catalytic
cysteine at position 139 of the enzyme is rapidly modified by the
inhibitor. The high-resolution structure of the complex provides
the first detailedinformationonhow anoroviral proteaserecognizes
its peptide substrate and provides a foundation for the knowledge-
based design of inhibitors as antiviral prophylactics.
MATERIALS AND METHODS
ProteinExpression and Purification. cDNA specifying the
3C proteinase was obtained as described in ref 10.E x p r e s s i o no f
theproteasewasachievedbygeneratingasegmentofDNAusing
PCR primers designed to form extensions of 38 bp upstream of
the50 endofthe proteasecodingregion and 1022 bp downstream
of the 30 end. The 50 primer was designed to include a NdeIs i t e
encoding the ATG start codon followed by commonly used
Escherichia coli codons specifying the C-terminal amino acids of
the VPg protein which precedes the protease in ORF 1. The 30
primer contained a BamHI site and bases specifying the N-
terminal part of the 3D RNA polymerase gene which follows
the protease in ORF 1. The amplified DNA was introduced into
the expression vector pRSET (UCB)at the NdeIa n dBamHI
restriction sites by standard methods, and the resulting plasmid
was transformed into E. coli BL21(DE3) pLysS. For overexpres-
sion,thesecellswhichweregrowninLuria-Bertanimediumwith
50 μg/mL ampicillin in shaken flasks at 37  Ca n di n d u c e du s i n g
isopropylβ-D-thiogalactopyranoside(IPTG)whichwasaddedto
a final concentration of 1 mM for the last 3 h of cell growth. The
harvestedcellsweresonicated,andfollowingultracentrifugation,
thesupernatantwasappliedtoacolumnofSP-Sepharosecation-
exchange matrix (GE Healthcare) in 10 mM phosphate buffer
atpH7.65containing5mM2-mercaptoethanol,followedby
elution with a gradient up to 1 M NaCl. After desalting with a
Sephadex G25 column, the enzyme was applied to a Source 15S
column (GE Healthcare) in the same buffer, followed by elution
with a gradient up to 1 M NaCl. After a final desalting step with
Sephadex G25, the protein was obtained in a yield of approxi-
mately 20 mg/L of culture and was concentrated to 10 mg/mL
a n ds t o r e di n5 0 %g l y c e r o l .T h eMr of the purified enzyme was
determined by electrospray massspectrometry as 19258, which is
FIGURE 1: Diagramatic representation of Southampton norovirus nonstructural polyprotein showing the protease cleavage sites. The scissile
bonds are shown arrowed, and the amino acid residue numbers are shown for the cleavage sites. The functions of the mature viral proteins are
indicated below the bars.
FIGURE 2: Structureofthe Michaelacceptor peptidylinhibitor (MAPI) designedtobespecificfor the Southampton virus3Cprotease(SV3CP).
The site of nucleophilic attack by the active site thiol is indicated.242 Biochemistry, Vol. 50, No. 2, 2011 Hussey et al.
consistentwiththepredictedaminoacidsequenceof181residues
and confirmed that the protease had self-excised from the flank-
ing sequences encoded by the expression construct.
Chromogenic Substrate Synthesis, Kinetic Assay, and
Inhibitor Synthesis. For kinetic studies of the protease specifi-
city, a series of peptides was synthesized, each withp-nitroaniline
(pNA) at the C-terminus to provide a convenient spectropho-
tometricassayoftheSV3CPactivity.Thefollowingchromogenic
peptides, Ac-QLQ-pNA, Ac-FQLQ-pNA, Ac-EFQLQ-pNA, and
Ac-DEFQLQ-pNA, were synthesized using a combination of
standard Fmoc solid-phase chemistry and synthetic techniques
(20). MALDI-Q-TOF-MS was used to confirm correct synthesis
following reverse-phase purification of each product in DMSO.
Each peptide mimics the SV3CP recognition sequence within the
200 kDa ORF 1 polyprotein which experiences the greatest rate
of cleavage (10). All peptides were synthesizedwith an acetylated
N-terminus and the C-terminus linked to a chromogenic pNA
group(21,22).WhereastheuncleavedchromogenicpNApeptide
iscolorless,cleavageoftheC-terminalp-nitroanilidegroupyields
free p-nitroaniline which is strongly yellow in color, and its
production can be followed spectrophotometrically at 405 nm.
The C-terminal glutamine-pNA presents an issue during peptide
chain extension since the C-terminal residue of a peptide would
normally be attached to the support resin via its main-chain
carboxyl. In this instance, pNA has to be attached at the
glutamine carboxyl, and therefore this residue must be linked to
the support resin by its side chain. Hence, the pNA derivative of
glutamate, rather than glutamine, was synthesizedandlinkedvia
its side chain to a Rink amide MBHA resin (23). Upon cleavage
from the resin, the side-chain carboxyl is aminated to yield a
glutamine residue.
TherateofcleavageofeachpNAsubstratebytheproteasewas
monitored at 405 nm using a Nanodrop ND1000 spectropho-
tometer. The assay involved dissolving the substrates in DMSO
and diluting them into a solution containing 100 mM Tris, pH
8.5, and 5 mM β-mercaptoethanol to give final substrate concen-
trationsinthe0.1-3.0mMrangeandafinalenzymeconcentration
of0.1mg/mLSV3CP.Theabsorbanceat405nmof2μLsa mp le s
taken from the reaction mixture was measured at 1 min intervals
over a 10 min period.
SinceitwasfoundthatAc-EFQLQ-pNAhadthehighestkcat/KM
ratio(seeResults),aMichael-acceptorpolypeptideinhibitor
(MAPI) with the same sequence as the optimal substrate was
synthesized, essentially by minor adaptation of the methods
described by Dragovich et al. (14), and purified by reverse-phase
chromatography (full details are given in the Supporting Infor-
mation). The inhibitor (shown in Figure 2) has the sequence Ac-
EFQLQ-X, where X is the propenyl ethyl ester extension to the
C-terminal residue which behaves as a Michael acceptor, under-
going nucleophilic attack by the active site thiol and generating a
stable thioether product (24). The success of each step in the
synthesis and the purity of the final compoundwas confirmed by
MALDI-Q-TOF-MS.
Crystallization and Preliminary X-ray Analysis. For the
initialcrystallizationstudies,samplesofproteasethatwerestored
in glycerol were exchanged using a Sephadex G25 column into
10mMphosphatebuffer,pH7.45,containing5mMβ-mercapto-
ethanolandthenconcentratedto3mg/mL.Crystalsofthenative
enzyme were obtained by the vapor diffusion method in several
conditionsatroomtemperatureusingtheJenaBiosciencesclassic
screens, and following further screening the optimum conditions
were found to be 7% PEG 8000 and 0.1 M HEPES, pH 7.5, with
8% (v/v) ethylene glycol. Preliminary data collection using station
ID14-1 at the ESRF (Grenoble, France) with crystals frozen in
30% glycerol (added stepwise) revealed that they belonged to a
hexagonalpoint group andproduced diffraction datatomedium
resolution.
Crystals of vastly improved diffraction quality were obtained
by forming a complex of the protease with the irreversible
inhibitor MAPI. To obtain these cocrystals, NaCl was added
to the protein sample to a final concentration of 300 mM which
allowed the protease to be concentrated to 17 mg/mL using a
10 kDa cutoff Centricon concentration vessel. To provide suitable
conditions to form a complex of the protease with the essentially
insolubleinhibitor,itwasnecessarytoinclude10%DMSOinthe
buffer. An amount of inhibitor giving a 3-fold molar excess over
theproteinwasdissolvedinavolumeofDMSOthatwould,once
added to the protein sample, result in the final buffer containing
10% DMSO. The inhibitor in DMSO was added to the protein
sample in 10 equal volumes at 10 min intervals. The sample was
then passed through a Sephadex G25 minispin column to rid the
complex of any excess unbound inhibitor and DMSO. Incuba-
tion of a small sample of the complex with the chromogenic
substrate Ac-EFQLQ-pNA demonstrated that 100% inhibition
had been achieved. Further confirmation and accurate assess-
mentof MAPI binding wereaccomplished by massspectrometry
which revealed a single major protein peak at 20045 Da corre-
sponding to one molecule of SV3CP plus one molecule of the
inhibitor. With the complex at a concentration of 15 mg/mL,
large crystals were obtained in 25% (w/v) PEG 5000 MME,
100 mM Tris-HCl, pH 8.5, and 200 mM lithium sulfate (Jena
Bioscience screen condition JB4 A1). Data collection at station
ID23-1 (ESRF, Grenoble) established that the crystals diffracted
to high resolution. Data processing in MOSFLM (25), SCA-
LA(26),and other programs inthe CCP4suite (27) revealed that
the crystals belonged to the space group P212121 with unit cell
dimensionsa=49.5A ˚ ,b=84.1A ˚ ,an dc=121.5A ˚ ;thedataset
had an overall Rmerge of 5.3% to 1.7 A ˚ resolution.
Preparation of selenomethioninyl protease for experimental
phasing involved the E. coli cells harboring the expression con-
struct being grown at 37  C to midlog phase in LB medium with
50 μg/mL ampicillin. The cells were then pelleted by centrifuga-
tion prior to resuspension in M9 minimal medium supplemented
with 0.4% (w/v) glucose and ampicillin at the above concentra-
tion. They were then grown at 37  Cf o r3 0m i nt ou s eu p
remaining amino acids prior to the addition of each of the
20 standard amino acids to final concentrations of 40 mg/L with
the exception of methionine, which was replaced by L-seleno-
methionine at the same final concentration. The cultures were
supplemented with the vitamins riboflavin, niacinamide, pyri-
doxine and thiamin, each at a final concentration of 1 mg/L, and
were shaken at 37  C for another 20 min. The cultures were then
induced by addition of IPTG to a final concentration of 1 mM
and grown for a further 3 h at 37  C. Purification of the
selenomethioninyl protease was performed as for the native
enzyme and yielded approximately 12 mg/L of culture. Analysis
oftheproteinbyelectrospraymassspectrometryshowedthatthe
molecular mass of the Se-Met enzyme was 19518 Da, indicating
100% occupancy of the five Se-Met residues per molecule.
Crystals of the selenomethionyl protease complexed with the
inhibitor were then grown and frozen as described above.
MAD Phasing and Refinement. Multiwavelength anoma-
lous diffraction data were collected on station ID23-1 at the
ESRF (Grenoble, France) to 1.8 A ˚ resolution using 1  oscillationsArticle Biochemistry, Vol. 50, No. 2, 2011 243
and an exposure time of 1 s per image. The data at each wave-
lengthwerescaledandprocessedasaboveinspacegroupP212121
(see Table 1 for details). The Se sites and phases were determined
usingSOLVE(28),whichgaveameanfigureofmeritof0.56,and
density modification using DM (29) gave an excellent electron
density map from which an initial model of the structure was
obtained using MAID (30) and manual building using TURBO-
FRODO (BioGraphics, Marseille). The model was refined with
the 1.7 A ˚ resolution “native” data set for the inhibitor complex
using the programs SHELX (31)a n dC N S( 32). Validation tests
were performed with MOLPROBITY (33), and buried solvent-
accessible areas were calculated using AreaIMol (27). The final
coordinates and structure factors have been deposited in the
ProteinDataBank(www.wwpdb.org)withaccessioncode2IPH.
RESULTS
Kinetic Evaluation of the Trial Substrates. Measurement
of the initial rates of cleavage of the chromogenic pNA peptides
establishedthatAc-EFQLQ-pNAwasthebestsubstrateinterms
ofspecificityconstant(kcat/KMratio);seeTable2.Incontrast,the
shortestpeptide,Ac-QLQ-pNA,wasnotcleavedatallduringthe
10 min assay period. The longest substrate, Ac-DEFQLQ-pNA,
had a kcat which was higher than that of Ac-EFQLQ-pNA
although its proportionately higher KM m e a n tt h a ti tw a sa
slightly inferior substrate in terms of specificity constant. The
remainingsubstrate,Ac-FQLQ-pNA,wascleavedwithakcat/KM
ratio that was significantly lower than that of optimal substrate.
These results facilitated the design and synthesis of the inhibitor
MAPI(Figure 2) withasequencewhich matchesthatofthe most
efficiently cleaved substrate, Ac-EFQLQ-pNA. Preincubation of
the enzyme with millimolar concentrations of the inhibitor, prior
to addition of substrate, was found to inactivate the enzyme
irreversibly within the dead time of the experiment (<30 s).
FormationofthecomplexofSV3CPwiththisinhibitorprovedto
be critical in obtaining a crystal form of the enzyme that
diffractedtohighresolutionandallowedstructuredetermination
to proceed.
Three-Dimensional Structure Analysis. The structure of
theSV3CPinhibitorcomplexhasbeenrefinedat1.7A ˚ resolution
to an R-factor and Rfree of 20.5% and 22.3%, respectively. The
electron density is clearly defined for all residues in both
molecules in the asymmetric unit except for a few amino acids
at the N-terminus of one monomer and a few side chains in the
loop regions of both molecules. The active site-directed inhibitor
is clearly shown to be covalently linked to Cys 139 as well as
making numerous other interactions with the protein. The two
molecules of the protease in the asymmetric unit are very closely
relatedstructurallywithanrmsdeviationinCRatompositionsof
only 0.4 A ˚ , excluding a partly disordered loop region formed by
residues 123-130 and a few residues at the N-terminus. Valida-
tion by MOLPROBITY (33) placed all residues within allowed
regionsoftheRamachandranplot(98.3%infavoredregionsand
1.7% in permissible regions).
Tertiary Structure of the Complex. Commensurate with
the crystallographic structures of other viral 3C proteases, e.g.,
PV (34), HAV (35, 36)a n dH R V( 37), the SV3CP structure
displays a chymotrypsin-like fold consisting of two domains
connected by a large loop (38). The amino acid sequence of
SV3CP and its associated secondary structure are shown in
Figure 3 along with a sequence alignment with other family
members. Domain I consists of a short N-terminal two-turn
R-helicalregionleadingdirectlyintothefirstoffiveβ-strands,βaI
to βeI (Figure 3), that comprise a twisted antiparallel β-sheet.
Domain I contributes a number of regions that interact with the
Table 1: Crystallographic and Refinement Statistics
a
space group P212121
unit cell dimensions
a (A ˚ ) 49.5
b (A ˚ ) 84.1
c (A ˚ ) 121.5
data set peak inflection remote native
λ (A ˚ ) 0.97925 0.97955 0.97625 0.93400
resolution (A ˚ ) 40.5-2.2 (2.3-2.2) 46.0-2.5 (2.6-2.5) 49.2-2.5 (2.6-2.5) 40.5-1.7 (1.8-1.7)
Rmerge (%)
b 8.6 (74.1) 5.7 (13.7) 6.4 (15.8) 5.3 (62.3)
completeness (%) 99.5 (98.7) 98.2 (99.9) 97.6 (100.0) 98.8 (92.8)
average I/σ(I) 29.3 (3.5) 22.8 (10.5) 20.7 (8.4) 22.4 (2.4)
multiplicity 19.6 (18.0) 6.7 (6.4) 6.6 (6.3) 6.7 (5.2)
refinement
c
R-factor (%) 20.5
Rfree factor (%) 22.3
no. of reflections 51760
rmsd bond lengths (A ˚ ) 0.005
rmsd bond angles (deg) 1.3
mean B-factor for all atoms (A ˚ 2) 27.3
aValues for the outer resolution shell of each data set are shown in parentheses; note that data to only 3.0 A ˚ were used in the initial phasing.
bRmerge = P
h
P
i|(Ihi - Ih)|/
P
h
P
i(Ihi), where Ih is the mean intensity of the scaled observations Ihi.
cAll data to 1.7 A ˚ resolution with no σ(I) cutoff were used in the
refinement except for 5% of the data which were reserved for the Rfree set.
Table 2: Kinetic Data for the Hydrolysis of pNA Substrates by SV3CP
a
substrate KM (M) kcat (s
-1) kcat/KM (M
-1 s
-1)
Ac-QLQ-pNA
Ac-FQLQ-pNA 1.5   10
-3 0.08 55
Ac-EFQLQ-pNA 3   10
-4 0.14 463
Ac-DEFQLQ-pNA 8   10
-4 0.33 416
aThe smallest substrate Ac-QLQ-pNA was not cleaved detectably, and
so no parameters could be determined.244 Biochemistry, Vol. 50, No. 2, 2011 Hussey et al.
active site ligand. These are the first β-hairpin loop (residues
12-15) and the loops involving residues 29-47 and 53-54.
Domain II is connected to domain I by a 20-residue loop and is
substantially larger than domain I, extending from Ile 72 to Glu
181. This domain consists of six β-strands, βaII to βfII, that
comprise an antiparallel β-barrel. The catalytic Cys 139 is
contained within the large loop linking βcII and βdII, and
accordingly, domain 2 forms the bulk of the interactions with
active site ligand (Figure 4a,b).
The electron density clearly shows that the active site thiol of
Cys 139 is bound covalently to the C-terminal Michael-acceptor
extension of the inhibitor MAPI (Figure 4c). Two further
members of the active site, Glu 54 and His 30, are within feasible
bonding distances and complete a putative triad of catalytic
residues (see Figure 4b). The involvement of Glu 54 in catalysis
was indicated when an E54A mutant was found to exhibit
diminished protease activity, although it was not found to be
absolutely required for activity (19). This is consistent with other
cysteine proteases which,compared toserine proteases,generally
exhibit a much reduced requirement for the third member of the
catalytic triad, due to the stronger nucleophilicity of the thiol (or
thiolate) group.
The β-strands βbII and βcII are of note since they form an
“arch” which covers the peptide portion of MAPI (Figure 4b). A
structure without the inhibitor bound might have wrongly
suggested that substrate would bind through the cleft generated
between domains I and II. However, it is clear that the β-barrel
motif of domain II will form the bulk of the interactions with
peptide substrates. For example, extensive β-sheet-like interac-
tions with the ligand are made by the C-terminal end of β-strand
βeII involving residues 158-161 which have the following
sequence: -Ala-Ala-Ala-Thr- (Figure 4c,d).
The twisted β-sheet motif of domain I possesses a notable
difference in its tertiary structure when compared with the PV,
HAV, and HRV 3C proteases which, in contrast, display a
complete β-barrel in this domain. The long loop, lpcI, consisting
of 19 residues (Thr 29-Ile 47) connecting βcI to βd I ,i sw e l l -
defined by the electron density but lacks any distinguishable
secondary structure, and it seems plausible that if it were to
possess more β-strand-like character, domain I might adopt a
complete β-barrel fold. Further evidence that domain I can be
consideredanincompleteβ-barrelratherthanatwistedβ-sheetis
offered in the form of a marked hydrophobic core, a common
feature of β-barrel motifs. The core of this domain is comprised
of the following, predominantly aromatic residues: Phe 12, Trp
19, Phe 25, Ile 32, Phe 39, Phe 40, Ile 47, Ile 49, Phe 58, Phe 60,
and Ile 64. Interestingly, one end of the hydrophobic core is
“capped” by Leu 180 at the C-terminal end of the protein. In
contrast, domain II displays a complete β-barrel, the core of
which is comprised of the following predominantly aliphatic
residues, Val 85, Ile 87, Leu 95, Leu 97, Val 99, Leu 121, Val 152,
Val 167, and Val 171, and the somewhat less hydrophobic
residues, Tyr 143, Tyr 145, and His 157. This β-barrel motif is
important in the orientation of the residues Tyr 143 and His 157
that are intrinsic to substrate binding at the S1 subsite. In addi-
tion, this domain contains a number of buried sulfur-containing
residues, as will be discussed later.
Gel-filtration studies showed that the SV3CP enzyme is
predominantly dimeric in solution. Accordingly, there are two
monomersinthecrystallographicasymmetricunitwhichhavean
interface that is maintained by a network of hydrogen bonds
between residues of RaI, βaII, lpaII andβbIIand lpcII (Figure 5)
resulting in a total buried surface area of 2353 A ˚ 2,w h i c hi s
suggestive of a physiologically relevant dimer. However, the
SV3CP dimer interface presented here is at odds with that of the
3C protease belonging to the Norwalk noroviral strain (18). This
structuresuggeststhatresiduesonanentirelydifferentfaceofthe
molecule are involved in dimer formation, which raises the
possibility that the dimer interface of the protease might differ
between noroviral strains.
CysteineClusterinDomainII.DomainIIcontainsacluster
ofcysteineresidues(comprisingCys77,Cys83,Cys154,andCys
169) which is reminiscent of a “cysteine cage” structure that is
normally involved inmetal coordination. However,the distances
between the cysteine sulfurs are in the range of 4-6A ˚ and are
therefore slightly greater than would be expected for a true
cysteine cage (approximately 3.5 A ˚ ), which probably stems from
theabsenceofacoordinatingmetalion.Indeed,the2Fo- Fcand
Fo - Fc density maps revealed a complete lack of density for a
coordinating metal ion, and the enzyme showed activity without
FIGURE 3: (a) Sequence alignment of SV3CP with other noroviral proteases. The sequences were obtained from the UniProtKB/SWISSPROT
sequence databank with the following accession numbers: Southampton virus Q04544, Norwalk-like virus Q83883, Lordsdale virus P54634,
Camberwell virus Q9W183, and Chiba virus Q9DU47. The amino acids are colored according to the following scheme: cyan = basic, red =
acidic, green = neutral-polar, pink = bulky hydrophobic, white = Gly, Ala, and Pro, and yellow = Cys. The secondary structure elements
presentinSV3CPareindicatedinthebottomrow.(b)AtopologydiagramofSV3CPwiththeputativeactivesitecatalyticresiduesCys139,His30,
and Glu 54 indicated in red.Article Biochemistry, Vol. 50, No. 2, 2011 245
any exogenous metal ions. As a result it seems more appropriate
to call it a “cysteine cluster” rather than a cysteine cage, and its
structural role might be quite conventional. Located at the
opposite end of the domain II β-barrel to the active site, the
cysteines contribute to the hydrophobic core of the barrel.
Strengthening the hydrophobic nature of this cluster is a further
sulfur-containing hydrophobic residue, Met101. Interestingly,
the cysteine/methionine cluster is conserved in a number of
norovirus 3C proteases.
Flexible Active Site Loop of Domain II. Domain II
possesses a long flexible loop between βcII and βdII which
includes residues Thr123 to Asp131 that were refined in two
conformations within molecule 1 of the dimer and a third
conformation within molecule 2. The position of this loop close
to the active site suggests that it may interact with substrate P0
residues, although the details of such interactions cannot be
discernedatthisstagesincetheinhibitordoesnotincluderesidues
ontheC-terminalsideofthescissilebond.Hence,thisloopmight
become more ordered when the P10 region of the natural sub-
strate is bound. The Chiba and Norwalk 3C protease struc-
tures (17, 18) lack any bound substrate analogue, and both show
similar flexibility in this region, suggesting that the observed
disorder is not simply an artifact of crystal packing with SV3CP
and that it may have a functional significance. The same loop
region is also involved in the dimer interface, implying that it
could be involved in quaternary structural changes, should any
take place upon substrate binding or during catalysis. Inspection
of the dimer interface reveals that three residues in this loop, Thr
123, Ala 125, and Asp 131, make significant intersubunit inter-
actions. Thr 123 interacts directly with Ser 84 that lies within the
βaII strand, Ala 125 interacts via a water molecule with Val 82
that also lies within βaII, and Asp 131 interacts directly with Trp
FIGURE 4: (a) SV3CP viewed through the β-barrel ofdomainII. The putative active site catalytic triad ofresiduesCys 139, His 30, and Glu 54is
indicatedinred.Residuesdelineatingthesecondarystructureelementsareindicatednumerically.TheconformationoftheinhibitorMAPIbound
toCys139isshowninvioletin(b).Theβ-strandsβbIIandβcIIcreateanarchthatbindswiththepeptidylportionofMAPI(correspondingtothe
naturalsubstratePresidues).(c)ElectrondensityfortheinhibitorMAPI.Theresiduesoftheinhibitorareshownalongwiththe2Fo-Fcelectron
density at 1.7 A ˚ resolution contoured at 1 rms. The contiguous electron density between Q1 and Cys 139 (shown on the far right) is evident; the
side-chain sulfur atom is colored green. (d) The β-sheet-like hydrogen-bonding network between the active site cleft residues of SV3CP and the
inhibitor MAPI. The SV3CP residues are shown in green and those of MAPI in pink. A number of water-mediated hydrogen bonds are also
shown, and donor-acceptor atom distances are given in A ˚ .
FIGURE 5: The dimeric arrangement of SV3CP observed in the
crystal structure. Residues involved in the interface are shown in
red for molecule 1 and green for molecule 2.246 Biochemistry, Vol. 50, No. 2, 2011 Hussey et al.
6 and via water molecules with Thr 4 and Leu 5 that all lie within
the N-terminal R-helix, RaI.
Binding of the Peptidyl Portion of the Inhibitor. For ease
of identification, the residues of the peptide portion of the
inhibitor MAPI are named E5, F4, Q3, L2, and Q1, correspond-
ing to residues in the N- to C-terminal direction, Glu, Phe, Gln,
Leu, and Gln, respectively. The corresponding enzyme subsites
are named S5 to S1 according to the nomenclature of Schechter
and Berger (39) in which the substrate residues are labeled
Pn-Pn0,w h e r eP 1 -P10 represents the scissile dipeptide.
As is typical of chymotrypsin-like proteases, the enzyme binds
the inhibitor via a hydrogen-bonding network in the manner of
an antiparallel β-sheet (Figure 4d). Although such interactions
involvingthemain-chainatomsofthesubstrate(orinhibitor)are
not directly responsible for defining specificity, they are likely to
be of great importance in correctly positioning the substrate
backbone in relation to the catalytic residues. The key interac-
tions are between Ala 160 and MAPI Q3 and between Ala 158
and MAPI Q1. The MAPI Q3 backbone carbonyl O and NH
hydrogen bond to the peptide NH and carbonyl O of Ala 160,
respectively, as is typical of an antiparallel β-sheet. A further
main-chain to main-chain hydrogen bond exists between the
carbonyl O of Ala 158 and the peptide NH of MAPI Q1.
Additionalhydrogenbondswiththeinhibitorincludethepeptide
NH of MAPI L2 and the Oε1 of Gln 110, the carbonyl O of
MAPI F4, and the peptide NH of Gln 110 via a water molecule,
aswellasthepeptideNHofMAPIF4andthecarbonylOofArg
108, also via a water molecule.
The S5 pocket is rather poorly defined due to the limited
number of interactions at this subsite, although kinetic measure-
ments demonstrate that occupation of the S5 site affects the rate
ofsubstratecleavagesignificantly,sincesubstratelackingP5(Ac-
FQLQ-pNA) has a much lower kcat/KM than Ac-EFQLQ-pNA
(Table 2). The main-chain carbonyl O of E5 hydrogen bonds via
a surface water molecule to the main-chain NH of Lys162, and a
second interaction, mediated by a water molecule, occurs be-
tweentheside-chaincarboxylateofE5andthemain-chainNHof
Gln 110. Comparison of residues at the P5 position of the five
points of cleavage within the natural substrate, Asp, Glu ( 2),
Ser, and Lys, reveals a diversity of residue types (10). The ability
of the enzyme to accommodate a range of residues at the P5
position is presumably due to the lack of specific side-chain
interactions at this subsite, although the presence of a P5 residue
significantly enhances the rate of cleavage. The observation that
this subsite is at the extremity of the active site cleft is consistent
with the kinetic data which show no enhancement in kcat/KM
when the peptide is extended to P6.
In spite of its surface-exposed location, the S4 binding pocket
iscomprisedpredominantlyofhydrophobicresiduesMet107,Ile
109, and Val 168 along with the aliphatic side-chain moieties of
Thr 161 and Thr 166, all of which interact with the Phe side
chain of the inhibitor. Sequence comparison of the five ORF 1
polyprotein cleavage sites shows that the following predomi-
nantly hydrophobic residues are present at the P4 position: Phe
( 2 ) ,A l a ,I l e ,a n dT h r( 10). The P4 main-chain NH and CO
groups interact by hydrogen bonding via ordered water mole-
cules to the carbonyl O of Arg 108 and main-chain NH of Gln
110, respectively.
For the Chiba virus 3C protease structure (17), it has been
suggestedthatthesidechainsofGln110andLys162acttoclamp
substrate at the P4 position by forming a bridge under which the
main chain of the substrate lies, and this feature appears to be
present in the SV3CP structure (Figure 6) although the two
residues are only interacting in one of the monomers, and they
appear tohave a greater roleinbinding at the adjacentP3 site. In
the monomer where Gln 110 and Lys 162 interact, the side chain
ofGlnP3isoriented towardthe side chain ofGln P1sothat they
form a hydrogen bond. In the other monomer, where Gln 110
and Lys 162 do not interact, the P3 side chain is oriented away
from the catalytic center (Figure 6).
The P3 main chain is held by an antiparallel β-sheet-like
hydrogen-bonding pattern involving its main-chain carbonyl
and amide which interact with the main-chain NH and CO
groups of Ala 160, respectively, as shown in Figure 4d. This
antiparallel β-sheet-like hydrogen-bonding pattern is typical of
otherchymotrypsin-likeproteases.Comparisonoftheresiduesat
the P3 position of the five cleavage sites of the natural substrate,
His, Gln, Thr ( 2), and Ser, reveals a diversity of amino acid
types, suggesting that the nature of the side chain at P3 is less
important for substrate binding than the main-chain interac-
tions(10).Accordingly,thestructureclearlyshowstheside-chain
groupofGlnP3isnotpositionedwithinadefinedbindingpocket
and the side chain can adopt more than one conformation, as
shown in Figure 6.
The buried, hydrophobic, and relatively large S2 binding
pocket is comprised of the following amino acids: His 30 (one
of the catalytic residues), Ile 109, and Val 114, as well as the
aliphatic moieties of Gln 110 and Arg 112. The generally
hydrophobic nature of the pocket is underlined by the absence
of any solvent molecules and a relative dearth of hydrogen bond
interactions between the enzyme and the inhibitor, although the
main-chainNH of P2interacts viahydrogenbonding tothe side-
chain Oε1 of Gln 110. Comparison of the five points of cleavage
in the ORF 1 polyprotein reveals that the residues at the P2
positionalwayspossessahydrophobicsidechain:Leu( 3),Met,
and Phe (10). Accordingly, the large size of the S2 pocket allows
FIGURE 6: Coordination of the inhibitor side chain at S3 in both
monomers.ThedisorderoftheMAPIQ3sidechainisindicated,asis
that of the Gln 110/Lys 162 clamp. For molecule 1 of the SV3CP
dimer, the Gln 110 and Lys 162 side chains are shown in blue, and
MAPIisshowninlightblue.Formolecule2oftheSV3CPdimer,the
Gln 110/Lys 162 clamp and the corresponding rendered surface are
shown in green, with MAPI in pink. Movement of the Lys 162 side
chain from the open “skewed” position to the closed “bridged”
position appears to be coupled to rotation of the χ1 torsion angle of
the MAPI Q3 side chain. The resultant conformation of Q3 is
stabilized by hydrogen bonding between side-chain O of MAPI Q3
and side-chain N of MAPI Q1.Article Biochemistry, Vol. 50, No. 2, 2011 247
theP2Leusidechaintobeinthegauchepositive(gþ)orientation
in molecule 1 and in the trans (t) conformation in molecule 2 of
the dimer (Figure 6). This bifurcation is consistent with the
known ability of the S2 pocket to accommodate larger hydro-
phobic residues such as Met and Phe.
The S1 and S10 binding pockets arguably play the most
importantroleinsubstratesequencerecognitionandorientation.
Comparison of the five dipeptide sequences that occupy the S1
and S10 sites, QG ( 2), EG ( 2), and EA, suggests that the
enzymewillacceptonlyaGlnorGluattheS1siteandonlyaGly
orAlaattheS10 site(10).InspectionofthestructureshowstheS1
siteisrelativelylargeandabletoaccommodatetheGlnsidechain
of the inhibitor in a fully extended conformation. It is clear from
the biochemical evidence alone that the S1 site differs quite
dramatically from the S10 binding site which is only able to
accommodate the small side chains of glycine and alanine.
Structurally, the S1 binding site is less distinctive than the S2
andS4sites,althoughtheP1Glnside chaincan clearlybeseento
lie parallel to and sandwiched between loop lpcII and the
C-terminal region of the β-strand βeII (Figure 7). The residues
Thr 134 of lpcII and His 157 of βeII are located at the end of the
S1binding pocket and hydrogen bond withthe P1Glnside chain
(presumablyGluatthispositioncanmakethesameinteractions).
Thr134andHis157arethereforelikelytobeofgreatimportance
insubstraterecognitionandindefiningsubstratespecificityatthe
S1 site. The important role played by His 157 has been demon-
strated bymutationalstudies (19) which showed that a His157A-
la mutant displays a reduced rate of substrate turnover, pre-
sumably due to a reduction in the affinity for substrate. It also
appears that Tyr 143 may play an important role in substrate
interactions at the S1 site, though not directly. The structure
suggeststhat,forcorrectorientationoftheHis157sidechain,the
OH group of Tyr 143 must hydrogen bond with the Nδ1o fH i s
157 so that the imidazole is oriented to hydrogen bond with the
substrate side chain occupying the S1 site.
Inspection of the map reveals a paucity of electron density for
the ethyl ester extension of the inhibitor, suggesting that it has
been hydrolyzed to yield a carboxylate group which appears to
interact with the catalytic His 30 and Gly 137. The Nε2o fH i s3 0
hydrogen bonds to the carboxylate via water molecules whereas
the main-chain amide nitrogen of Gly 137 makes a direct inter-
action. The latter residue is likely to constitute part of the
oxyanion-binding hole of the enzyme. Hence it appears that
fortuitous hydrolysis of the ethyl ester moiety to generate a
C-terminal carboxylate provides a unique structural insight into
the nature of the oxyanion hole. The pseudo-first-order rate
constant for base-catalyzed hydrolysis of n-alkyl carboxylic acid
esters at the pH of crystallization (pH 8.5) is approximately
0.03 day
-1 (40, 41), which suggests that, following formation of
the enzyme-inhibitor complex, the ethyl ester group will be
substantially hydrolyzed during the 3 week crystallization period
at ambient temperature by nonenzymic processes. However,
thereisweakelectrondensityfor the ethyl group inthe structure,
suggesting that although the extent of hydrolysis is significant, it
is not complete.
In both molecules of the SV3CP-MAPI complex, the side
chain of His 30 is separated by too great a distance from the side
chains of Glu 54 and Cys 139 to allow the necessary hydrogen
bonding required to form the putative catalytic triad. With
MAPI covalently bound to the Sγ of Cys 139, it appears that
the His 30 side chain adopts a conformation pointing away from
Cys 139 and Glu 54. Indeed, the His 30 side chain appears to
interact electrostatically with the C-terminal carboxylate of the
hydrolyzed inhibitor. In the absence of the inhibitor, the His 30
side chain would most likely adopt a conformation in which the
imidazole is within hydrogen-bonding distance of both Cys 139
and Glu 54. This agrees with the biochemical and structural
studiesofarelatedenzyme(17,19)whichshowedthatitisindeed
His 30 and not His 157 (which is also close to Cys 139) that
participates in catalysis.
Prediction of the S0 Substrate Binding Sites of SV3CP.
Visual inspection of a surface-rendered model of the SV3CP-
MAPI structure suggests that the substrate P0 residues may be
bound in a rather deep surface cleft that follows on from the
S5-S1 sites occupied by MAPI. Hence, the S10 binding site is
likely to consist of residues Ser 14, Val 31, and Gly 137 and the
catalytic residue Cys 139. Biochemical evidence suggests the P10
residue of the substrate always possesses a small side-chain
group, therefore requiring only a small S10 pocket in which to
be accommodated. The relatively close proximity of Ser 14, Val
31, Gly 137, and Cys 139 would provide such a small-sized S10
binding pocket.
The subsequent S0 sites are less easy to define although it is
possible to suggest two putative routes along which they may lie.
Asdiscussedabove,theflexibleloopregioncomprisedofresidues
Thr 123 to Asp 131 may contribute to substrate binding at the S0
sites. The most obvious route for the P0 residues directly follows
thedeepsurfacecleftmentionedinthepreviousparagraph;thisis
shown as “route I” in Figure 8. If substrate were to lie along this
route, the residues that would interact with it are Lys 11, Ser 14,
Trp 16, Arg 89, Asp 90, Ser 91, Ile 135, Gly 137, and Asp 138 as
well as residues in the disordered loop involving 123-131.
Alternatively, substrate could lie along the route named “route
II” in Figure 8, although this is dependent upon the conforma-
tions of Lys 11 and Asp 90 when ligand is bound. From visual
inspection of the structure it seems possible that these residues
may operate as a clamp in a similar manner to the Gln 110/Lys
162 clamp. If so, the putative Lys 11/Asp 90 clamp may bind the
substrate P30 or P40 residues. However, in the absence of a
structure for a ligand occupying the S0 sites of any noroviral
protease, this hypothesis remains speculative. For the substrate
to follow the alternative route (route I) it would have to kink
FIGURE 7: TheS1-S10 bindingsitesofSV3CP.Theresiduesinvolved
incoordinationofMAPIattheS1bindingsiteincludingGly137and
His157whichhydrogenbondwiththeQ1sidechain.Gly137isalsoa
member of the putative oxyanion hole. The loop lpcII and the
β-strand βeII form a cleft that accommodates the side chain of P1.248 Biochemistry, Vol. 50, No. 2, 2011 Hussey et al.
appreciablyatP10 andP20 (seeFigure8),whichwouldbeentirely
consistent with the preference of the enzyme for the conforma-
tionally disruptive residues Gly and Pro at these positions of the
substrate.
DISCUSSION
The use of a peptide irreversible inhibitor with a sequence
based on that of the most rapidly cleaved site of the viral
polyprotein (EFQLQ-GKMYD) has permitted the detailed
nature of substrate binding by a noroviral 3C protease to be
elucidated structurally for the first time. This work establishes
thattheN-terminalGluofthepeptideislargelyoutsidetheactive
site cleft, and relatively few direct contacts with the enzyme are
evident. In contrast, the P4 residue, Phe, makes many contacts
with the enzyme, and the observation that the chromogenic
peptide Ac-FQLQ-pNA is cleaved but that Ac-QLQ-pNA is not
suggests that the S4 binding site plays a very important role in
productive substrate binding. The main chain of the substrate at
P3 interacts extensively with the enzyme, although the side chain
has some flexibility. The known cleavage sites for the SV3C
protease possess a hydrophobic residue in the S2 subsite, and
accordingly the structure confirms this is a region of extensive
contacts between the enzyme and substrate, which is typical of
other cysteine proteases.Withinthe viralpolyproteinthisresidue
may be Leu (three occurrences), Met (one occurrence), or Phe
(oneoccurrence)(10).Inthecurrentstudythereasonforthepref-
erence for a hydrophobic residue is clear since there are several
nonpolar residues making up the S2 site, including the hydro-
phobic side chains of Ile 109, Val 114, and Ala 159. In addition,
themethylenechainsofGln110 andArg112 formoppositesides
of the S2 site.
SV3C protease is relatively specific for the residues on either
sideofthescissilebondandcanonlycleavesignificantlywhenthe
P1 residue is Gln or Glu and the P10 residue is very small such as
Gly or Ala, the optimal combination being Gln-Gly. The most
important residues at the far extremity of the S1 site appear to be
Thr134andHis157which makehydrogenbondswiththeamide
group of Gln.
The relativelack ofspecificity of the enzyme at several subsites
close to the scissile bond can be rationalized by the structural
studies, which demonstrate that these pockets allow the ligand
side chains to adopt more than one conformation. Similar con-
formational heterogeneity is observed for residues of the enzyme
that form these pockets.
One further feature of the enzyme which, although not
absolutely conserved in noroviral proteases, raises a number of
intriguing questions is the buried cysteine cluster in domain II.
Perhaps the sensitivity of the enzyme to oxidizing environments
can be partly attributed to disulfide formation. In addition, it
may be that these residues have a physiological role in the viral
life cycle as a “redox switch”, possibly preventing excessive
proteolysis following maturation of the virus particle.
Based partly on the accepted mechanism of catalysis by
cysteine proteases, the SV3CP structure presented here sheds
light on a number of specific details of the enzyme-catalyzed re-
action. As described above, the structure establishes that the
catalytically important members of the active site are Cys 139,
His 30, and potentially Glu 54. The latter residue is likely to
facilitate catalysis by immobilizing the His 30 side chain via a
hydrogen bond such that the imidazole can act as a Brønsted-
LowrybasetodeprotonateCys139.Withthecorrectpositioning
of the substrate within the active site cleft, the scissile bond is
broughtintosufficientlycloseproximitywithCys139tofacilitate
nucleophilic attack by the thiolate on the carbonyl C of the
scissile peptide and yield an unstable, covalently bound tetra-
hedral intermediate. During nucleophilic attack on the substrate
carbonyl group, the shift of negative charge onto the carbonyl O
would probably be favored by hydrogen bonds involving the
backbone amide nitrogens of Cys 139 and Gly 137 that are likely
to form the oxyanion hole. We propose that Asp 138 does not
contribute to the oxyanion hole, as suggested by others (18),
although we suggest that it is vital in orientation of the oxyanion
hole members through indirect means. The peptide NH of Asp
138 hydrogen bonds to the main-chain carbonyl O of Ile 135,
thereby stabilizing the type II reverse turn that correctly orients
the peptide N-H group of Gly 137 toward the main-chain
nitrogen of Cys 139 to form the oxyanion hole. Collapse of the
tetrahedral intermediate complex is promoted by His 30, now
acting as a Brønsted-Lowry acid, protonating the substrate
amide N. This results in formation of an acyl-enzyme intermedi-
ate and the amine product (i.e., the C-terminal portion of the
substrate)whichdissociatesfromtheactivesitecleft.Diffusionof
a water molecule into the catalytic site followed by nucleophilic
attackonthesubstratecarbonylcarbon,promotedbyHis30and
potentially Glu 54, results in hydrolysis of the acyl-enzyme and
release of the N-terminal portion of the substrate.
Further work on this enzyme will structurally define the
binding pockets forming the “prime” side of the active site cleft,
will allow the relevance of the putative dimeric states observed in
the crystal structures tobeassessed, andwillaidthe development
of further inhibitory compounds with therapeutic potential.
SUPPORTING INFORMATION AVAILABLE
Full details of the synthesis of the Michael-acceptor polypep-
tideinhibitor(MAPI).Thismaterialisavailablefreeofchargevia
the Internet at http://pubs.acs.org.
FIGURE 8: The predicted S0 binding sites of SV3CP. The S10 site is
likelytobecomprisedoftheresiduesSer14,Val31,Gly137,andCys
139. The subsequent P0 residues may lie along one of two routes
labeled “route I” and “route II” (shown as thick pale blue arrows).
The residues predicted to form the S0 sites of “route I” are colored in
cyan.Thealternativeroute(II)wouldinvolvethesubstratebeingheld
at P30 or P40 by the putative clamp formed of Lys 11 and Asp 90.
MAPI is shown in pink.Article Biochemistry, Vol. 50, No. 2, 2011 249
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